Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT/LDRT+PD-1+GP for r/mNPC
NCT06323239Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 12 months. Started Jul 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06323239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323239.